期刊文献+

老年上皮性卵巢癌患者血清人附睾上皮分泌蛋白4的变化及临床意义 被引量:4

Change and its clinical significance of serum level of human epididymis secretory protein 4 in elderly patients with epithelial ovarian cancer
原文传递
导出
摘要 目的 探讨老年上皮性卵巢癌患者血清中人附睾上皮分泌蛋白4(human epididymis protein 4,HE4)的改变及其临床意义.方法 用ELISA法检测老年上皮性卵巢癌33例、良性卵巢疾病17例及老年健康女性20例血清HE4水平,另选同期非老年上皮性卵巢癌患者31例及健康女性20例为对照,同时测定糖类抗原125(CA125).结果 健康人群中≥60岁组血清HE4水平(32.25±13.15)pmol/L高于<60岁组(24.59±8.60)pmol/L,血清HE4水平与年龄呈显著正相关(r=0.525,P<0.01).老年组中上皮性卵巢癌患者血清HE4水平明显高于卵巢良性疾病患者(中位数81.50 pmol/L对45.60 pmol/L,U=168.5,P<0.05)和健康对照者(中位数81.50 pmol/L对33.30 pmo1/L,U=76.5,P<0.01);根据受试者操作特性曲线(ROC曲线)分析,HE4检测老年上皮性卵巢癌的临界值为65.43 pmol/L时,其敏感度为66.67%,特异性为86.49%,与CA125相比曲线下面积为0.799比0.782,HE4诊断价值稍高于CA125;老年与非老年上皮性卵巢癌患者血清HE4水平比较,差异无统计学意义(U=404.2,P>0.05).结论 年龄是影响人血清HE4水平的重要生理因素,HE4测定有助于老年人上皮性卵巢癌的诊断,与CA125联合检测,可显著提高诊断的准确性. Objective To investigate the change and clinical significance of the serum level of human epididymis secretory protein 4 (HE4) in elderly patients with epithelial ovarian cancer (EOC).Methods The serum levels of HE4 were determined by ELISA in EOC patients (n= 33), benign ovarian disease patients ( n = 17) and healthy women ( n = 20), all of them aged 60 years or over. And there were other 31 EOC patients and 20 healthy women aged less than 60 years at the same period as controls. Results In healthy people, the serum level of HE4 was higher in the group with age ≥60 years than with age 〈60 years [(32.25± 13. 15) pmol/L vs. (24.59±8.60) pmol/L]. The serum HE4 level had a positive correlation with age (r=0. 525, P〈0.01). The median level of HE4 was significantly higher in elderly EOC patients than in benign ovarian disease patients (81.50 pmol/L vs.45.60 pmol L, U=168.5, P〈0.05) and healthy women (81.50 pmol L vs. 33.30 pmol L, U=76.5, P〈0. 01). The HE4 had a significantly higher area under ROC curve when compared with CA125 (0. 799 vs. 0. 782), while the cut-off value was set 65.43 pmol L with a sensibility and specificity of 66.67% and 86.49% respectively. The diagnostic efficacy of HE4 was higher than CA125. There was no significantly statistical difference between elderly and non-elderly EOC patients in serum HE4 levels (U= 101.2, P〉0. 05). Conclusions Age is an important factor which can affect human serum level of HE4. HE4 determination is helpful in the diagnosis of ovarian epithelial carcinoma in the elderly patients, and the combined detection of HE4 and CA125 is an useful adjuvant diagnostic measure.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2010年第12期996-998,共3页 Chinese Journal of Geriatrics
关键词 附睾分泌蛋白类 卵巢肿瘤 Epididymal secretory protein Ovarian Neoplasms
  • 相关文献

参考文献9

  • 1Schummer M,Ng WV,Bumgarner RE,et al.Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas.Gene,1999,238:375-385.
  • 2Hellstrom I.Rayeraft J.Hayden-Ledbetter M.et al.The HE1 (WFDC2)protein is a biomarker for ovarian carcinoma.Cancer Res,2003,63:3695-3700.
  • 3Montagnana M,Lippi G,Ruzzenente O,et al.The utility of serum human epididymis protein 4 (HE4) inpatients with a pelvic mass.J Clin Lab Anal,2009,23:331-335.
  • 4Kirchhoff C,Habben I,Ivell R,et al.A major human epididymis-specific cDNA encodes a protein with sequence homology to extraeellular proteinase inhibitors.Biol Reprod,1991,45:350-357.
  • 5Xi Z,LinLin M,Ye T.Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system.J Clin Lab Anal,2009,23:357-361.
  • 6Bingle L,Cross SS,High AS,et al.WFDC2 (HE4):apotential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung.Respir Res,2006,7:61.
  • 7Galgano MT.Hampton GM.Frierson HF.et al.Comprehensive analysis of HE4 expression in normal and malign ant human tissues.Mod Pathol,2006,19:817-853.
  • 8胡晓舟,崔丽艳,张捷.健康人群血清HE4水平参考区间的初步探讨[J].中华检验医学杂志,2009,32(12):1376-1378. 被引量:27
  • 9Mousavi AS,Boma S.Moeinoddini S.Estimation of probability of malignancy using a logistic model combining color Doppler ultrasonography serum CA125 level in women with a pelvic mass.Int J Gynecol Cancer,2006,16:92-98.

二级参考文献7

  • 1Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors, 1991, 45 : 350- 357.
  • 2Wang K, Gan L, Jeffery E, et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene, 1999, 229 : 101-108.
  • 3Drapkin R, yon Homten HH, Lin Y, et al . Human epididymis protein 4 (HFA) is a secreted glycoprotcin that isoverexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 2005, 65:2162-2169.
  • 4Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res,2003, 63:3695-3700.
  • 5Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol,2008,108: 402-408.
  • 6Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Modem Path,2006, 19:847-853.
  • 7Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2) is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene, 2002, 21: 2768-2773.

共引文献26

同被引文献78

  • 1Penny F Whiting,Marie E Weswood,Anne WS Rutjes,Johannes B Reitsma,Patrick NM Bossuyt,Jos Kleijnen,马章淳,钱楠.QUADAS评价:一种用于诊断性研究的质量评价工具(修订版)[J].中国循证医学杂志,2007,7(7):531-536. 被引量:64
  • 2Andersen MR,Goff BA,Lowe KA,et al.Use of a Symptom Index,CA125,and HE4 to predict ovarian cancer[J].Gynecol Oncol,2010,116(3):378-383.
  • 3Drapkin R,von HHH,Lin Y,et al.Human epididymis protein 4 (HE4) is a secreted glycoprotcin that is overexpressed by serous and endometrioid ovarian carcinomas[J].Cancer Res,2005,65(6):2162-2169.
  • 4Hellstrom I,Raycraft J,Hayden-Ledbetter M,et al.The HE4 (WFDG2) protein is a biomarker for ovarian cardnoma[J].Cancer Res,2003,63(13):3695-3700.
  • 5Van Gorp T,Gadron I,Despierre E,et al.HE4 and CA125 as a diagnostic test in ovarian cancer:prospective validation of the Risk of Ovarian Malignancy Algorithm[J].Br J Cancer,2011,104(5):863-870.
  • 6Jacob F,Meier M,Caduff R,et al.No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting[J].Gynecol Oncol,2011,121(3):487-491.
  • 7Shah CA,Lowe KA,Paley P,et al.Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers meso thelin,HE4,and CA125[J].Cancer Epidemiol Biomarkers Prev,2009,18(5):1365-1372.
  • 8Nolen B,Velikokhatnaya L,Marrangoni A,et al.Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass[J].Gynecol Oncol,2010,117(3):440-445.
  • 9Moore RG,Brown AK,Miller MC,et al.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecol Oncol,2008,108(2):402-408.
  • 10Abdel-Azeez HA,Labib HA,Sharaf SM,et al.HE4 and mesothelin:novel biomarkers of ovarian carcinoma in patients with pelvic masses[J].Asian Pac J Cancer Prev,2010,11(1):111-116.

引证文献4

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部